[go: up one dir, main page]

AR060038A2 - Una molecula de anticuerpo anti-ige que no exhibe desactivacion de isomerizacion de aspartilo y que tiene afinidad con la molecula objetivo ige y molecula de acido nucleico - Google Patents

Una molecula de anticuerpo anti-ige que no exhibe desactivacion de isomerizacion de aspartilo y que tiene afinidad con la molecula objetivo ige y molecula de acido nucleico

Info

Publication number
AR060038A2
AR060038A2 ARP070101154A ARP070101154A AR060038A2 AR 060038 A2 AR060038 A2 AR 060038A2 AR P070101154 A ARP070101154 A AR P070101154A AR P070101154 A ARP070101154 A AR P070101154A AR 060038 A2 AR060038 A2 AR 060038A2
Authority
AR
Argentina
Prior art keywords
molecula
ige
nucleic acid
aspartile
affection
Prior art date
Application number
ARP070101154A
Other languages
English (en)
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of AR060038A2 publication Critical patent/AR060038A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/81—Drug, bio-affecting and body treating compositions involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, immunotolerance, or anergy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)

Abstract

Estas moléculas son utiles para la manufactura de un medicamento util para reducir o evitar la produccion de histamina mediada por IgE. Reivindicacion 1: Una molécula de anticuerpo caracterizado porque tiene una secuencia de cadena liviana y una secuencia de cadena pesada que exhibe al menos un 70% de identidad de la secuencia a la secuencia de cadena liviana y la secuencia de cadena pesada "e27" (Sec. ID. Ns 19 & 21) y que comprende los residuos CDR1 de la cadena liviana variable, 32Glu, 27Lys y 28Pro. Reivindicacion 3: Una molécula de ácido nucleico caracterizada porque tiene una secuencia que exhibe al menos un 85% de identidad a una que codifica para "e27" (Sec. ID. Ns 19 & 21), en donde dicha molécula de ácido nucleico codifica una molécula de anticuerpo que comprende los residuos CDR1 de la cadena liviana variable, 32Glu, 27Lys y 28Pro, de acuerdo con la reivindicacion 1.
ARP070101154A 1997-07-02 2007-03-21 Una molecula de anticuerpo anti-ige que no exhibe desactivacion de isomerizacion de aspartilo y que tiene afinidad con la molecula objetivo ige y molecula de acido nucleico AR060038A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/887,352 US5994511A (en) 1997-07-02 1997-07-02 Anti-IgE antibodies and methods of improving polypeptides

Publications (1)

Publication Number Publication Date
AR060038A2 true AR060038A2 (es) 2008-05-21

Family

ID=25390964

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP980103225A AR013169A1 (es) 1997-07-02 1998-07-02 UN MÉTODO PARA PREPARAR UN POLIPÉPTIDO MODIFICADO QUE ES UN ANTICUERPO ANTI-IGE QUE NO EXHIBE DESACTIVACION DE ISOMERIZACIoN DE ASPARTILO Y QUE TIENE AFINIDAD A LA MOLÉCULA OBJETIVO IGE, UNA MOLÉCULA DE ANTICUERPO, UNA MOLECULA DE ACIDO NUCLEICO, UNA COMPOSICIoN Y USO DE UN ANTICUERPO PARA LA MANUFA
ARP070101154A AR060038A2 (es) 1997-07-02 2007-03-21 Una molecula de anticuerpo anti-ige que no exhibe desactivacion de isomerizacion de aspartilo y que tiene afinidad con la molecula objetivo ige y molecula de acido nucleico

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP980103225A AR013169A1 (es) 1997-07-02 1998-07-02 UN MÉTODO PARA PREPARAR UN POLIPÉPTIDO MODIFICADO QUE ES UN ANTICUERPO ANTI-IGE QUE NO EXHIBE DESACTIVACION DE ISOMERIZACIoN DE ASPARTILO Y QUE TIENE AFINIDAD A LA MOLÉCULA OBJETIVO IGE, UNA MOLÉCULA DE ANTICUERPO, UNA MOLECULA DE ACIDO NUCLEICO, UNA COMPOSICIoN Y USO DE UN ANTICUERPO PARA LA MANUFA

Country Status (28)

Country Link
US (4) US5994511A (es)
EP (1) EP0996728B1 (es)
JP (2) JP4286327B2 (es)
KR (1) KR100547538B1 (es)
CN (1) CN1260357C (es)
AR (2) AR013169A1 (es)
AT (1) ATE253116T1 (es)
AU (1) AU741115B2 (es)
BR (2) BRPI9810654C1 (es)
CA (1) CA2295540C (es)
CZ (1) CZ300724B6 (es)
DE (1) DE69819332T2 (es)
DK (1) DK0996728T3 (es)
ES (1) ES2210778T3 (es)
HU (1) HU228845B1 (es)
IL (2) IL133973A0 (es)
IS (1) IS2039B (es)
NO (1) NO324992B1 (es)
NZ (1) NZ501842A (es)
PL (1) PL194562B1 (es)
PT (1) PT996728E (es)
RO (1) RO120848B1 (es)
RU (1) RU2242515C2 (es)
SK (1) SK284395B6 (es)
TR (1) TR200000206T2 (es)
TW (2) TWI233946B (es)
WO (1) WO1999001556A2 (es)
ZA (1) ZA985500B (es)

Families Citing this family (187)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US20040197326A1 (en) * 1995-07-27 2004-10-07 Genentech, Inc. Method for treatment of allergic asthma
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US20040146507A1 (en) * 1996-11-27 2004-07-29 Genentech, Inc. Antibody mutants
US7122636B1 (en) 1997-02-21 2006-10-17 Genentech, Inc. Antibody fragment-polymer conjugates and uses of same
US5994511A (en) * 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
US6172213B1 (en) * 1997-07-02 2001-01-09 Genentech, Inc. Anti-IgE antibodies and method of improving polypeptides
US7393529B2 (en) * 1998-04-09 2008-07-01 Idexx Laboratories, Inc. Methods and compositions for inhibiting binding of IgE to a high affinity receptor
US6504013B1 (en) 2000-02-01 2003-01-07 Idexx Laboratories, Inc. Canine allergy therapeutic recombinant chimeric anti-IgE monoclonal antibody
US6818749B1 (en) * 1998-10-31 2004-11-16 The United States Of America As Represented By The Department Of Health And Human Services Variants of humanized anti carcinoma monoclonal antibody cc49
US7759133B2 (en) * 1998-12-22 2010-07-20 Alk-Abello A/S Method of detecting and/or quantifying a specific IgE antibody in a liquid sample
GB9908533D0 (en) 1999-04-14 1999-06-09 Novartis Ag Organic compounds
US20020019009A1 (en) * 1999-12-09 2002-02-14 Roggen Erwin Ludo High throughput screening (HTS) assays
EP1242576B1 (en) * 1999-12-14 2005-04-13 Thermo Biostar, Inc. Stabilizing diluent for polypeptides and antigens
EP1261376A1 (en) * 2000-01-27 2002-12-04 Genetics Institute, LLC Antibodies against ctla4(cd152), conjugates comprising same, and uses thereof
US7018801B2 (en) * 2000-02-11 2006-03-28 Board Of Regents, The University Of Texas System Selection of peptides with antibody-like properties
US20030143638A1 (en) * 2000-04-07 2003-07-31 Mahito Hirai Antibody/carrier complex, process for producing the same, method of controlling antigen-antibody reaction by using the same and immunoassay method
US6951947B2 (en) * 2000-07-13 2005-10-04 The Scripps Research Institute Labeled peptides, proteins and antibodies and processes and intermediates useful for their preparation
US7176037B2 (en) * 2000-07-13 2007-02-13 The Scripps Research Institute Labeled peptides, proteins and antibodies and processes and intermediates useful for their preparation
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
WO2002030463A2 (en) * 2000-10-12 2002-04-18 Genentech, Inc. Reduced-viscosity concentrated protein formulations
ES2727425T3 (es) 2000-12-12 2019-10-16 Medimmune Llc Moléculas con semividas prolongadas, composiciones y usos de las mismas
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US20050118164A1 (en) * 2001-03-09 2005-06-02 William Herman Targeted ligands
US6966992B2 (en) * 2001-03-19 2005-11-22 Akzo Nobel Nv Method of purification of molecules using unbranched terminal alkyldiols
AU2002327171A1 (en) * 2001-05-01 2003-01-02 Medimmune, Inc. Crystals and structure of synagis fab
US20040146502A1 (en) * 2001-05-03 2004-07-29 Elisabeth Latour Use of organic compounds
GB0113179D0 (en) 2001-05-31 2001-07-25 Novartis Ag Organic compounds
US20030087372A1 (en) * 2001-06-13 2003-05-08 Genentech, Inc. Methods of culturing animal cells and polypeptide production in animal cells
US20030073249A1 (en) * 2001-07-07 2003-04-17 Lee Duen Allergen detection chip
JP2003137804A (ja) * 2001-10-31 2003-05-14 Morinaga Milk Ind Co Ltd インターロイキン−１８誘導剤
US7179798B2 (en) * 2001-11-16 2007-02-20 Russell R. Roby Methods and compositions for the treatment of pain and other hormone-allergy-related symptoms using dilute hormone solutions
AU2002362197A1 (en) * 2001-12-28 2003-07-24 Chugai Seiyaku Kabushiki Kaisha Method of stabilizing protein
WO2003057168A2 (en) * 2002-01-03 2003-07-17 The Scripps Research Institute Cancer-associated epitope
GB0200429D0 (en) * 2002-01-09 2002-02-27 Novartis Ag Organic compounds
US20050142539A1 (en) * 2002-01-14 2005-06-30 William Herman Targeted ligands
AU2003210802B2 (en) * 2002-02-05 2009-09-10 Genentech Inc. Protein purification
AU2003222664A1 (en) * 2002-04-18 2003-11-03 Genencor International, Inc. Production of functional antibodies in filamentous fungi
CA2490659C (en) * 2002-06-28 2014-08-19 Syed V. S. Kashmiri Humanized anti-tag-72 cc49 for diagnosis and therapy of human tumors
KR101103218B1 (ko) * 2002-11-08 2012-01-05 아블린쓰 엔.브이. 종양 괴사 인자-알파에 대한 단일 도메인 항체 및 그 용도
US20100003253A1 (en) * 2002-11-08 2010-01-07 Ablynx N.V. Single domain antibodies directed against epidermal growth factor receptor and uses therefor
US20060034845A1 (en) * 2002-11-08 2006-02-16 Karen Silence Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
ES2655912T3 (es) * 2002-11-08 2018-02-22 Ablynx N.V. Anticuerpos de dominio simple dirigidos contra factor de necrosis tumoral-alfa y usos para los mismos
US9320792B2 (en) 2002-11-08 2016-04-26 Ablynx N.V. Pulmonary administration of immunoglobulin single variable domains and constructs thereof
EP2258392A1 (en) * 2002-11-08 2010-12-08 Ablynx N.V. Method of administering therapeutic polypeptides
US20060034833A1 (en) * 2002-11-08 2006-02-16 Els Beirnaert Single domain antibodies directed against interferron-gamma and uses therefor
US7056702B2 (en) * 2002-12-16 2006-06-06 Kimberly Clark Co Detecting lipocalin
DK2000481T3 (en) * 2003-02-01 2016-06-06 Tanox Inc High affinity anti-human IgE antibodies
US20060234296A1 (en) * 2003-02-01 2006-10-19 Sanjaya Singh Method for generating high affinity antibodies
WO2004078965A1 (ja) * 2003-03-05 2004-09-16 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute 大腸菌における異種蛋白質の製造方法
US20050158303A1 (en) * 2003-04-04 2005-07-21 Genentech, Inc. Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
CA2519408C (en) * 2003-04-04 2011-01-18 Genentech, Inc. High concentration antibody and protein formulations
GB2401040A (en) 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
KR100988129B1 (ko) * 2003-04-30 2010-10-18 쥬리디컬 파운데이션 더 케모-세로-쎄라퓨틱 리서치 인스티튜트 인간 항인간 인터루킨-18 항체와 그 단편, 및 이들의이용방법
US20090263381A1 (en) * 2003-07-31 2009-10-22 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anti-ige antibody for treatment of asthma or chronic obstructive pulmonary disease
US20050026881A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anti-IgE antibody for treatment of asthma or chronic obstructive pulmonary disease
US20050065136A1 (en) * 2003-08-13 2005-03-24 Roby Russell R. Methods and compositions for the treatment of infertility using dilute hormone solutions
WO2005021594A2 (en) 2003-08-29 2005-03-10 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Minimally immunogenic variants of sdr-grafted humanized antibody cc49 and their use
BRPI0414093A (pt) 2003-09-05 2006-10-31 Scripps Res Insittute produtos de ozonização de colesterol para o tratamento e prevenção de ateroesclerose e/ou doenças cardiovasculares
BRPI0414154A (pt) * 2003-09-05 2006-10-31 Scripps Resarch Inst detecção de produtos de ozonização do colesterol
JP2008500269A (ja) * 2003-10-08 2008-01-10 イーバイオサイエンス 天然免疫グロブリン結合試薬とその作製及び使用方法
EP1688432B1 (en) 2003-10-09 2011-08-03 Chugai Seiyaku Kabushiki Kaisha Igm high concentration stabilized solution
WO2005088308A2 (en) * 2004-03-12 2005-09-22 The Scripps Research Institute Fluorescent signal emitting live cell biosensor molecules and dyes for detection and quantification of protein activities
US8398980B2 (en) * 2004-03-24 2013-03-19 Chugai Seiyaku Kabushiki Kaisha Subtypes of humanized antibody against interleuken-6 receptor
US20090111702A1 (en) * 2004-04-06 2009-04-30 Mount Sinai School Of Medicine Office Of Industrial Liason Methods of determining allergen response using microarray immunoassay techniques
US20050239757A1 (en) * 2004-04-21 2005-10-27 Roby Russell R Hormone treatment of macular degeneration
GB0410627D0 (en) * 2004-05-12 2004-06-16 Scancell Ltd Specific binding members
US7604947B2 (en) * 2004-06-09 2009-10-20 Cornell Research Foundation, Inc. Detection and modulation of cancer stem cells
ZA200700947B (en) 2004-07-23 2008-06-25 Genentech Inc Crystallization of antibodies or fragments thereof
US20060025390A1 (en) * 2004-07-28 2006-02-02 Roby Russell R Treatment of hormone allergy and related symptoms and disorders
US7655229B2 (en) 2004-09-02 2010-02-02 Chan Andrew C Anti-FC-gamma RIIB receptor antibody and uses therefor
US7662926B2 (en) 2004-09-02 2010-02-16 Genentech, Inc. Anti-Fc-gamma receptor antibodies, bispecific variants and uses therefor
US20060051347A1 (en) 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
US20090017016A1 (en) * 2004-10-05 2009-01-15 Tanox Inc. Treatment and prevention of hypersensitivity and/or anaphylaxis with anti-ige antibodies in patients receiving replacement therapy
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
GT200600031A (es) * 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
RU2007124933A (ru) * 2005-01-28 2009-03-10 Вайет (Us) Стабилизированные жидкие полипептидные составы
GB0502358D0 (en) * 2005-02-04 2005-03-16 Novartis Ag Organic compounds
WO2006099747A1 (en) * 2005-03-25 2006-09-28 National Research Council Of Canada Method for isolation of soluble polypeptides
ES2417065T3 (es) 2005-04-26 2013-08-05 Trion Pharma Gmbh Combinación de anticuerpos con glucocorticoides para el tratamiento del cáncer
US8080249B2 (en) * 2005-06-30 2011-12-20 Risk Glifford G Methods to treating chronic obstructive pulmonary disease
PT1912675E (pt) 2005-07-25 2014-05-09 Emergent Product Dev Seattle Moléculas de ligaçao especificas para cd37 e especificas para cd20
WO2008020827A2 (en) * 2005-08-01 2008-02-21 Biogen Idec Ma Inc. Altered polypeptides, immunoconjugates thereof, and methods related thereto
AU2006297304B2 (en) * 2005-09-29 2012-05-17 Medimmune, Llc Method of identifying membrane LG specific antibodies and use thereof for targeting immunoglobulin-producing precursor cells
JP2007172129A (ja) * 2005-12-20 2007-07-05 Sony Corp 不揮発性メモリアクセス制御装置および不揮発性メモリ制御システム
CN101062949B (zh) * 2006-04-26 2011-07-27 上海抗体药物国家工程研究中心有限公司 重组抗人IgE单克隆抗体及其制备方法和用途
US8409577B2 (en) 2006-06-12 2013-04-02 Emergent Product Development Seattle, Llc Single chain multivalent binding proteins with effector function
FR2902799B1 (fr) 2006-06-27 2012-10-26 Millipore Corp Procede et unite de preparation d'un echantillon pour l'analyse microbiologique d'un liquide
KR20090069330A (ko) * 2006-10-12 2009-06-30 와이어쓰 유백광/응집체를 감소시키기 위한 항체 용액 중의 이온 강도의 변화
US8163886B2 (en) 2006-12-21 2012-04-24 Emd Millipore Corporation Purification of proteins
US8362217B2 (en) 2006-12-21 2013-01-29 Emd Millipore Corporation Purification of proteins
US8569464B2 (en) 2006-12-21 2013-10-29 Emd Millipore Corporation Purification of proteins
US20110212084A1 (en) * 2007-02-15 2011-09-01 Astrazeneca Ab Binding members for ige molecules
AR065368A1 (es) * 2007-02-15 2009-06-03 Astrazeneca Ab Anticuerpos para moleculas de ige
TWI464178B (zh) 2007-03-22 2014-12-11 Genentech Inc 細胞凋亡抗-ｉｇｅ抗體
SG182985A1 (en) * 2007-04-02 2012-08-30 Amgen Fremont Inc Anti-ige antibodies
RS58217B1 (sr) † 2007-04-03 2019-03-29 Amgen Res Munich Gmbh Interspecijski specifičan vezujući domen
EP2155788B1 (en) * 2007-04-03 2012-06-27 Micromet AG Cross-species-specific bispecific binders
ES2389618T3 (es) * 2007-04-16 2012-10-29 Momenta Pharmaceuticals, Inc. Productos de glucoproteínas definidas y métodos relacionados
AR066476A1 (es) * 2007-05-08 2009-08-19 Genentech Inc Anticuerpos anti-muc16 disenados con cisteina y conjugaods de anticuerpos y farmacos
KR102055873B1 (ko) 2007-07-09 2019-12-13 제넨테크, 인크. 폴리펩티드의 재조합 생산 동안의 디술피드 결합 환원의 방지
CN103554215B (zh) 2007-10-30 2016-06-15 健泰科生物技术公司 通过阳离子交换层析进行的抗体纯化
US20110183861A1 (en) * 2008-01-29 2011-07-28 Ablynn N.V. Methods to stabilize proteins and polypeptides
US20220281964A1 (en) * 2008-02-25 2022-09-08 Xencor, Inc. Fc VARIANTS WITH ALTERED BINDING TO FcRn
NZ603059A (en) 2008-04-11 2014-07-25 Emergent Product Dev Seattle Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
US8999702B2 (en) 2008-06-11 2015-04-07 Emd Millipore Corporation Stirred tank bioreactor
IT1391559B1 (it) * 2008-09-01 2012-01-11 Lofarma Spa Allergoidi derivati da allergeni
AU2009293143C1 (en) * 2008-09-17 2015-07-23 Xencor, Inc. Novel compositons and methods for treating IgE-mediated disorders
CN118324847A (zh) * 2008-10-29 2024-07-12 阿布林克斯公司 单域抗原结合性分子的纯化方法
EP2362767B1 (en) 2008-10-29 2017-12-06 Ablynx N.V. Formulations of single domain antigen binding molecules
CN102271708A (zh) * 2008-11-13 2011-12-07 新兴产品开发西雅图有限公司 Cd37免疫治疗联合疗法及其用途
WO2010068722A1 (en) 2008-12-12 2010-06-17 Medimmune, Llc Crystals and structure of a human igg fc variant with enhanced fcrn binding
SG171446A1 (en) 2008-12-16 2011-07-28 Millipore Corp Stirred tank reactor and method
EP2403874A1 (en) * 2009-03-06 2012-01-11 Genentech, Inc. Antibody formulation
JP5808052B2 (ja) 2009-05-29 2015-11-10 中外製薬株式会社 Ｅｇｆファミリーリガンドのアンタゴニストを成分とする医薬組成物
SI2473617T1 (sl) 2009-09-01 2020-07-31 F. Hoffmann-La Roche Ag Izboljšano prečiščevanje beljakovin z modificirano elucijo beljakovine A
NZ599600A (en) 2009-10-26 2015-04-24 Genentech Inc Assays for detecting antibodies specific to therapeutic anti-ige antibodies and their use in anaphylaxis
SG10201502587SA (en) 2010-03-01 2015-06-29 Bayer Healthcare Llc Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
KR20150002894A (ko) * 2010-03-11 2015-01-07 리나트 뉴로사이언스 코프. ｐＨ 의존성 항원 결합을 갖는 항체
RU2584232C2 (ru) 2010-03-22 2016-05-20 Дженентек, Инк. Композиции и способы, используемые для стабилизации белоксодержащих готовых форм
EP4450523A3 (en) 2010-04-02 2025-03-12 Amunix Pharmaceuticals, Inc. Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
US9921210B2 (en) 2010-04-07 2018-03-20 Momenta Pharmaceuticals, Inc. High mannose glycans
KR101726707B1 (ko) 2010-05-17 2017-04-13 이엠디 밀리포어 코포레이션 생체분자 정제용 자극 반응성 중합체
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
WO2012030512A1 (en) 2010-09-03 2012-03-08 Percivia Llc. Flow-through protein purification process
DE19177059T1 (de) 2010-10-01 2021-10-07 Modernatx, Inc. N1-methyl-pseudouracile enthältendes ribonucleinsäuren sowie ihre verwendungen
CN104998254A (zh) 2010-11-08 2015-10-28 基因技术公司 皮下施用的抗-il-6受体抗体
EP2686671A4 (en) 2011-03-12 2015-06-24 Momenta Pharmaceuticals Inc N-GLYCANES CONTAINING N-ACETYLHEXOSAMINE IN GLYCOPROTEIN PRODUCTS
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
CN107090038A (zh) 2011-06-30 2017-08-25 霍夫曼-拉罗奇有限公司 抗c‑met抗体配制剂
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
HUE057725T2 (hu) 2011-10-03 2022-06-28 Modernatx Inc Módosított nukleozidok, nukleotidok és nukleinsavak és ezek felhasználása
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
HRP20220717T1 (hr) 2011-12-16 2022-07-22 Modernatx, Inc. Modificirani pripravci mrna
WO2013096791A1 (en) 2011-12-23 2013-06-27 Genentech, Inc. Process for making high concentration protein formulations
TWI593705B (zh) 2011-12-28 2017-08-01 Chugai Pharmaceutical Co Ltd Humanized anti-epiregulin antibody and cancer therapeutic agent containing the antibody as an active ingredient
AR091305A1 (es) 2012-01-31 2015-01-28 Genentech Inc ANTICUERPOS ANTI-IgE Y SUS METODOS DE USO
WO2013120973A1 (en) * 2012-02-15 2013-08-22 Institut National De La Sante Et De La Recherche Medicale (Inserm) Method of producing high-affinity antibodies
JP2015516143A (ja) 2012-04-02 2015-06-08 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ヒト疾患に関連するタンパク質の産生のための修飾ポリヌクレオチド
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9303079B2 (en) 2012-04-02 2016-04-05 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
HRP20250525T1 (hr) 2012-05-18 2025-06-20 Genentech, Inc. Visokokoncentrirane formulacije monoklonskog protutijela
US20150140608A1 (en) * 2012-06-01 2015-05-21 Momenta Pharmaceuticals, Inc. Methods related to omalizumab
US9695244B2 (en) 2012-06-01 2017-07-04 Momenta Pharmaceuticals, Inc. Methods related to denosumab
FR2994390B1 (fr) 2012-08-10 2014-08-15 Adocia Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
WO2014041544A1 (en) * 2012-09-12 2014-03-20 Ramot At Tel-Aviv University Ltd. Immunoparticles and methods of generating and using same
SMT202200337T1 (it) 2012-11-26 2022-09-14 Modernatx Inc Rna modificato al livello del terminale
CA2897987A1 (en) 2013-01-15 2014-07-24 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
EP2855533A4 (en) 2013-03-15 2015-11-25 Momenta Pharmaceuticals Inc METHODS RELATING TO CTLA4-FC FUSION PROTEINS
US10464996B2 (en) 2013-05-13 2019-11-05 Momenta Pharmaceuticals, Inc. Methods for the treatment of neurodegeneration
KR101815265B1 (ko) 2013-06-20 2018-01-04 한올바이오파마주식회사 FcRn 특이적 인간 항체 및 이를 포함하는 자가면역 질환 치료용 조성물
US10196458B2 (en) * 2013-07-26 2019-02-05 The Regents Of The University Of California Anti-immunoglobulin E antibodies and methods of using thereof
KR20160042438A (ko) 2013-08-12 2016-04-19 제넨테크, 인크. 보체-연관 상태의 치료를 위한 조성물 및 방법
EP3052106A4 (en) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucleotides encoding immune modulating polypeptides
WO2015051214A1 (en) 2013-10-03 2015-04-09 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
EP3058084A4 (en) 2013-10-16 2017-07-05 Momenta Pharmaceuticals, Inc. Sialylated glycoproteins
NZ720161A (en) 2013-11-04 2022-07-29 Ichnos Sciences SA Production of t cell retargeting hetero-dimeric immunoglobulins
CA2929184A1 (en) 2013-11-13 2015-05-21 Genentech, Inc. Assisted manual injector devices and methods
MX2016014160A (es) 2014-05-01 2017-02-16 Genentech Inc Variantes del anticuerpo anti-factor d y sus usos.
JP6397938B2 (ja) * 2014-06-17 2018-09-26 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ Ｂリンパ球のＣＤ２３と架橋するが肥満細胞を感作しないヒト化抗ＩｇＥ抗体
WO2016007752A1 (en) 2014-07-09 2016-01-14 Genentech, Inc. Ph adjustment to improve thaw recovery of cell banks
EP3194449A1 (en) 2014-07-24 2017-07-26 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
US11773166B2 (en) 2014-11-04 2023-10-03 Ichnos Sciences SA CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production
WO2016164920A1 (en) 2015-04-09 2016-10-13 Cornell University Gene therapy to prevent reactions to allergens
US11352426B2 (en) 2015-09-21 2022-06-07 Aptevo Research And Development Llc CD3 binding polypeptides
EP3368074A2 (en) 2015-10-30 2018-09-05 Hoffmann-La Roche AG Anti-factor d antibodies and conjugates
WO2017075252A1 (en) * 2015-10-30 2017-05-04 Genentech, Inc. Anti-factor d antibody variant conjugates and uses thereof
GB201610198D0 (en) * 2016-06-10 2016-07-27 Ucb Biopharma Sprl Anti-ige antibodies
ES3034904T3 (en) 2016-07-18 2025-08-27 Univ Ramot Modular platform for targeted therapeutics
JP7127859B2 (ja) 2016-11-09 2022-08-30 ノース カロライナ ステート ユニバーシティ キメラタンパク質を用いたアレルギー疾患の治療
EP3558366A1 (en) 2016-12-22 2019-10-30 H. Hoffnabb-La Roche Ag Methods and formulations for reducing reconstitution time of lyophilized polypeptides
WO2018211517A1 (en) 2017-05-16 2018-11-22 Bhami's Research Laboratory, Pvt. Ltd. High concentration protein formulations with reduced viscosity
US11708418B2 (en) * 2017-08-10 2023-07-25 Grifols Diagnostic Solutions Inc. Compositions, methods and/or kits comprising a recombinant human CD38- extracellular domain
KR102652133B1 (ko) * 2018-02-01 2024-03-29 베이징 카윈 테크놀로지 쉐어-홀딩 컴퍼니 리미티드 IL-4Rα 항체 및 그 용도
CN111787947A (zh) 2018-02-09 2020-10-16 豪夫迈·罗氏有限公司 用于肥大细胞介导的炎性疾病的治疗和诊断方法
WO2019183437A1 (en) 2018-03-23 2019-09-26 North Carolina State University Methods and compositions for antibody to high affinity receptor for ige
WO2021250546A1 (en) 2020-06-09 2021-12-16 University Of Washington Micrornas as predictors of response to anti-ige therapies in chronic spontaneous urticaria
BR112023000400A2 (pt) * 2020-07-10 2023-03-21 Shanghai Jemincare Pharmaceuticals Co Ltd Anticorpo anti-ige engenheirado e aplicação do mesmo
CN111879923A (zh) * 2020-08-06 2020-11-03 深圳科隆生物新材料有限公司 一种可消除hama效应的试剂盒
CA3213283A1 (en) 2021-03-11 2022-09-15 IgGenix, Inc. Methods and systems for predicting allergic response
WO2024003825A1 (en) * 2022-06-29 2024-01-04 Kashiv Biosciences, Llc An improved assay method of antibody
US12509529B2 (en) * 2024-05-17 2025-12-30 Excellergy, Inc. Antibodies and antibody fragments that bind IgE

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4275149A (en) * 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
JPS6031471B2 (ja) * 1978-07-21 1985-07-22 協和醗酵工業株式会社 グリセロ−ル酸化酵素およびその製法
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8607679D0 (en) * 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5534617A (en) * 1988-10-28 1996-07-09 Genentech, Inc. Human growth hormone variants having greater affinity for human growth hormone receptor at site 1
SU1752763A1 (ru) * 1990-04-10 1992-08-07 Центральный научно-исследовательский рентгено-радиологический институт Штамм гибридных культивируемых клеток животных MUS MUScULUS L. - продуцент моноклональных антител к I @ Е человека
ES2113940T3 (es) * 1990-12-03 1998-05-16 Genentech Inc Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas.
WO1992017207A1 (en) 1991-03-26 1992-10-15 Tanox Biosystems, Inc. MONOCLONAL ANTIBODIES WHICH BIND TO SECRETED AND MEMBRANE-BOUND IgE, BUT NOT TO IgE ON BASOPHILS
DE122004000008I1 (de) * 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5965709A (en) * 1991-08-14 1999-10-12 Genentech, Inc. IgE antagonists
US6329509B1 (en) * 1991-08-14 2001-12-11 Genentech, Inc. Anti-IgE antibodies
EP0602126B1 (en) * 1991-08-14 2003-03-05 Genentech, Inc. Immunoglobulin variants for specific fc epsilon receptors
WO1993011161A1 (en) * 1991-11-25 1993-06-10 Enzon, Inc. Multivalent antigen-binding proteins
EP1514934B1 (en) * 1992-02-06 2008-12-31 Novartis Vaccines and Diagnostics, Inc. Biosynthetic binding protein for cancer marker
WO1994020533A1 (en) 1993-03-11 1994-09-15 Tanox Biosystems, Inc. PEPTIDES REPRESENTING ANTIGENIC EPITOPES OF IgE PRESENT ON B CELL BUT NOT BASOPHIL SURFACE
US5597710A (en) * 1994-03-10 1997-01-28 Schering Corporation Humanized monoclonal antibodies against human interleukin-4
US5561053A (en) 1994-08-05 1996-10-01 Genentech, Inc. Method for selecting high-expressing host cells
US5705154A (en) * 1995-03-08 1998-01-06 Schering Corporation Humanized monoclonal antibodies against human interleukin-4
US6037453A (en) * 1995-03-15 2000-03-14 Genentech, Inc. Immunoglobulin variants
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
ATE265861T1 (de) * 1995-08-17 2004-05-15 Protein Design Labs Inc Antikörper gegen l-selectin zur vorbeugung von multiplem organversagen und akuter organschädigung
US5994511A (en) * 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides

Also Published As

Publication number Publication date
KR20010014422A (ko) 2001-02-26
BR9810654B8 (pt) 2013-02-19
HUP0002474A3 (en) 2003-03-28
WO1999001556A3 (en) 1999-04-22
ES2210778T3 (es) 2004-07-01
TWI233946B (en) 2005-06-11
AU8270198A (en) 1999-01-25
JP4371248B2 (ja) 2009-11-25
SK187599A3 (en) 2001-08-06
CZ473599A3 (cs) 2000-06-14
DK0996728T3 (da) 2004-02-23
IS2039B (is) 2005-08-15
PL194562B1 (pl) 2007-06-29
US20020054878A1 (en) 2002-05-09
BR9810654B1 (pt) 2013-01-08
HK1027833A1 (en) 2001-01-23
NO996551D0 (no) 1999-12-29
NZ501842A (en) 2002-02-01
CZ300724B6 (cs) 2009-07-29
DE69819332T2 (de) 2004-07-15
EP0996728B1 (en) 2003-10-29
IS5321A (is) 1999-12-23
NO996551L (no) 2000-03-01
JP2002510211A (ja) 2002-04-02
JP4286327B2 (ja) 2009-06-24
HUP0002474A2 (hu) 2000-10-28
BRPI9810654C1 (pt) 2021-05-25
PT996728E (pt) 2004-03-31
CN1260357C (zh) 2006-06-21
KR100547538B1 (ko) 2006-01-31
CA2295540A1 (en) 1999-01-14
JP2009055902A (ja) 2009-03-19
IL133973A (en) 2006-12-10
US6682735B2 (en) 2004-01-27
IL133973A0 (en) 2001-04-30
US6761889B2 (en) 2004-07-13
ZA985500B (en) 1999-12-24
AU741115B2 (en) 2001-11-22
ATE253116T1 (de) 2003-11-15
AR013169A1 (es) 2000-12-13
HU228845B1 (en) 2013-06-28
RU2242515C2 (ru) 2004-12-20
BR9810654A (pt) 2005-10-04
US6290957B1 (en) 2001-09-18
SK284395B6 (sk) 2005-03-04
NO324992B1 (no) 2008-01-14
WO1999001556A2 (en) 1999-01-14
EP0996728A2 (en) 2000-05-03
PL338030A1 (en) 2000-09-25
RO120848B1 (ro) 2006-08-30
US5994511A (en) 1999-11-30
DE69819332D1 (de) 2003-12-04
TR200000206T2 (tr) 2000-07-21
CN1268176A (zh) 2000-09-27
CA2295540C (en) 2011-01-25
US20030149244A1 (en) 2003-08-07
TW570976B (en) 2004-01-11

Similar Documents

Publication Publication Date Title
AR060038A2 (es) Una molecula de anticuerpo anti-ige que no exhibe desactivacion de isomerizacion de aspartilo y que tiene afinidad con la molecula objetivo ige y molecula de acido nucleico
Deng et al. Multiple Light Control Mechanisms in ATP‐Fueled Non‐equilibrium DNA Systems
BR9611088B1 (pt) processo para a produção de um combustìvel destilado ou de uma alimentação de mistura de combustìvel destilado mais pesado do que a gasolina, e, uso de um combustìvel. destilado.
ES2165851T3 (es) Proteinas multivalentes que se unen a antigenos.
BR9808153A (pt) Processo para melhorar a fotossìntese
EP0283925A3 (de) Verfahren zur Reinigung resorbierbarer Polyester
BR9911129B1 (pt) n-alquiluretanos (i) de fructanos, seu uso, bem como sua composiÇço e processo para sua produÇço.
BR9808738B1 (pt) processo para fabricaÇço de laminado decorativo e laminado decorativo obtido pelo processo.
BR9807502B1 (pt) compostos orgÂnicos, processo para sua preparaÇço, bem como composiÇço e aplicaÇço dos mesmos.
ES2136415T3 (es) Procedimiento para la fabricacion de poliesteres utilizando combinaciones de catalizador que contiene titanio e inhibidor.
BR8903636A (pt) Processo para producao de material polimerico de propileno com ramificacao de cadeia longa,de elevado peso molecular,e processo para tratamento de material polimerico de propileno irradiado
DE69832938D1 (de) Krackkatalysator für die Produktion von leichten Olefinen und dessen Herstellung
BR8200744A (pt) Processo para formar uma superficie com baixa perda otica por espalhamento;fibra de nucleo otico
BR0211194A (pt) Produção de derivados de queratina solúveis
DK0990044T3 (da) En fremgangsmåde til en vitro-molekylær evolution af proteinfunktion
ES2165508T3 (es) Material polimerico, procedimiento para su fabricacion y su uso.
EP0695171A1 (en) GONADOTROPINE CONTAINING FREEZER DRIED DROPS
BR9404315A (pt) Catalisador, processo para sua preparação e processo para hidroconversão de hidrocarboneto.
ATE166882T1 (de) Monoklonale antikörper (mak) gegen tumorassoziierte antigene, ihre herstellung und verwendung
ES2084107T3 (es) Deteccion de analitos que poseen dominios de union para al menos dos fragmentos de union.
DE69007968D1 (de) Derivate von polyhydroxylierten molekülen, welche die einführung von mindestens einer verzweigung in ein oligonukleotid erlauben.
BR9917352B1 (pt) processo para polimerizar etileno e pelo menos uma ou mais outras(s) olefina(s) para produzir interpolìmero de etileno/olefina.
CY1109207T1 (el) Διαδικασια εχινοκανδινης
PT742821E (pt) Processo de preparacao de uma biblioteca multicombinatoria de vectores de expressao de genes de anticorpos
DE3877355D1 (de) Verfluessigung von cellulose.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal